FourKites has Expanded its Operations Into the United Kingdom

CHICAGO (PRWEB) November 30, 2018

FourKites, the leader in predictive supply chain visibility, announced today that it has expanded its operations into the United Kingdom, and plans to open other offices in Europe over the next few months.

FourKites currently tracks loads in more than 70 countries worldwide, working with top shippers and carriers across North America, South America, Europe and Africa. The FourKites platform is now live in eight languages, with product guides in fifteen languages.

FourKites has already been active in Europe since 2017. The company has onboarded hundreds of European carriers and is integrated with the top telematics providers in the region. The new European offices will enable FourKites to continue to service global customers and provide implementation and onboarding support to shippers and carriers across the European market.

“FourKites is proud to have built the world’s largest shipper network with on-the-ground presence in North America, South America, and Europe,” said Stephanie Kolaczynski, chief operating officer of FourKites. “Providing local resources for EU shippers and carriers ensures a relevant and timely experience for our customers.”

FourKites now has five office locations: Chicago (headquarters); Chennai, India; Mexico City, Mexico; Sao Paulo, Brazil; and Bristol, UK.

“Large, global shippers have seen the power that predictive visibility provides, and scaling internationally will help us provide unprecedented value to our customers,” said Mathew Elenjickal, founder and CEO of FourKites. “Our expanded presence in Europe will help our customers deliver exceptional service and operational excellence.”

About FourKites
FourKites is the fastest-growing predictive supply chain visibility platform, delivering real-time visibility and predictive analytics for the broadest network of Fortune 500 companies and third-party logistics firms. Using a proprietary algorithm to calculate shipment arrival times, FourKites enables customers to lower operating costs, improve on-time performance, and strengthen end-customer relationships. With a network of more than four million GPS/ELD devices, FourKites covers all modes including ocean, rail, parcel and over-the-road. The platform is optimized for mobile and equipped with market-leading end-to-end security. To learn more, visit https://www.fourkites.com. Reported by PRWeb 2 hours ago.

SEOUL, South Korea, Nov. 30, 2018 /PRNewswire/ -- Hanwha Q CELLS Co., Ltd. ("Hanwha Q CELLS" or the "Company") (NASDAQ: HQCL), a global leading photovoltaic manufacturer of high-performance, high-quality solar modules, today reported its unaudited financial results for the third quarter ended September 30, 2018. The Company will not be hosting a conference call to discuss these results.

*Third Quarter 2018 Highlights*

· Net revenues were $559.3 million, compared with $518.4 million in the second quarter of 2018 and $543.0 million in the third quarter of 2017.
· Gross margin was -6.3%, compared with 14.0% in the second quarter of 2018 and 11.6% in the third quarter of 2017. Excluding certain one-time effects, gross margin for the third quarter of 2018 was 13.0%.
· Operating loss was $107.0 million, compared with an operating income of $4.8 million in the second quarter of 2018 and operating income of $10.6 million in the third quarter of 2017. Excluding certain one-time effects, operating income for the third quarter of 2018 was $17.9 million.
· Net loss attributable to the Company's ordinary shareholders was $164.6 million, compared with net loss of $41.3 million in the second quarter of 2018 and net income of $5.0 million in the third quarter of 2017. Excluding certain one-time effects, net loss attributable to the Company's ordinary shareholders for the third quarter of 2018 was $39.7 million. Excluding these one-time effects as well as foreign exchange losses, net income attributable to Company's ordinary shareholders for the third quarter of 2018 was $2.7 million.
· Loss per fully diluted American Depositary Share ("ADS" and each ADS represents 50 of the Company's ordinary shares) was $1.98, compared with loss per fully diluted ADS of $0.50 in the second quarter of 2018 and income per fully diluted ADS of $0.06 in the third quarter of 2017. Excluding certain one-time effects, loss per fully diluted American Depositary Share for the third quarter of 2018 was $0.48. Excluding these one-time effects as well as foreign exchange losses, earnings per fully diluted American Depositary Share for the third quarter of 2018 was $0.03.

*Third Quarter 2018 Results of Operations*

Net Revenues

· Total net revenues were $559.3 million, up 7.9% from $518.4 million in the second quarter of 2018 and up 3.0% from $543.0 million in the third quarter of 2017. This was due to increased shipment volume, which mitigated the effects of declining ASPs, and an increase in demand for the Company's premium product, the Q.PEAK DUO, which was associated to the Company increasing and expanding its sales network within key regions.

Gross Profit and Margin

· Gross loss in the third quarter of 2018 was $35.3 million, compared to a gross profit of $72.6 million in the second quarter of 2018 and a gross profit of $63.2 million in the third quarter of 2017. Excluding a $108.2 million one-time loss associated with the discontinuation of the Company's China-based ingot manufacturing operations in September, gross profit for the third quarter of 2018 was $72.9 million. The Company concluded that it would be in its best interest to discontinue unprofitable operations and focus on its core business – the manufacturing of cells and modules. This decision was based on the fact that the current scale of ingot operations would preclude the Company from being competitive on a global scale, and while the discontinuation of ingot production resulted in a one-time loss, the Company believes it will improve long-term profitability by allowing us to focus its core competencies.
· Gross margin in the third quarter of 2018 was -6.3%, compared with 14.0% in the second quarter of 2018 and 11.6% in the third quarter of 2017. Excluding the one-time effects related to the discontinuation of ingot manufacturing operations, gross margin for the third quarter of 2018 was 13.0%.

Results of Operations and Operating Margin

· Loss from operations in the third quarter of 2018 was $107.0 million, compared with income from operations of $4.8 million in the second quarter of 2018 and $10.6 million in the third quarter of 2017. Excluding the one-time effects related to the discontinuation of ingot manufacturing operations as well as a $16.7 million allowance for bad debt on certain overdue receivables, operating income for the third quarter of 2018 was $17.9 million.
· Operating margin in the third quarter of 2018 was -19.1%, compared with 0.9% in the second quarter of 2018 and 2.0% in the third quarter of 2017. Excluding the one-time effects related to the discontinuation of ingot manufacturing operations and to certain overdue receivables, operating margin for the third quarter of 2018 was 3.2%.
· Total operating expenses were $71.7 million in the third quarter of 2018, up 5.8% from $67.8 million in the second quarter of 2018 and up 36.3% from $52.6 million in the third quarter of 2017. Excluding the one-time effects related to certain overdue receivables, total operating expenses for the third quarter of 2018 were $55.0 million.
· Selling and marketing expenses were $37.5 million in the third quarter of 2018, down 10.7% from $42.0 million in the second quarter of 2018 and up 22.5% from $30.6 million in the third quarter of 2017.
· General and administrative expenses were $30.0 million in the third quarter of 2018, up 42.9% from $21.0 million in the second quarter of 2018 and up 72.4% from $17.4 million in the third quarter of 2017. Excluding the one-time effects related to certain overdue receivables, general and administrative expenses for the third quarter of 2018 were $13.3 million.
· Research and development expenses were $4.2 million in the third quarter of 2018, down 12.5% from $4.8 million in the second quarter of 2018 and down 8.7% from $4.6 million in the third quarter of 2017.

Net Interest Expense

· Net interest expense was $14.1 million in the third quarter of 2018, compared with $15.2 million in the second quarter of 2018 and $10.0 million in the third quarter of 2017.

Foreign Currency Exchange Gain (Loss)

· Foreign currency exchange loss was $42.4 million in the third quarter of 2018, compared with a loss of $37.8 million in the second quarter of 2018 and a gain of $7.3 million in the third quarter of 2017. This was mainly due to a weak Turkish lira in relation to the U.S. dollar, causing a foreign currency exchange loss both in the second and third quarters.

Gain (loss) on Change in Fair Value of Derivative Contracts

· Loss on change in fair value of derivative contracts was $0.9 million in the third quarter of 2018, compared to a gain of $8.1 million in the second quarter of 2018 and a loss of $0.6 million in the third quarter of 2017.

Income Tax Expense (Benefit)

· Income tax expense was $1.2 million in the third quarter of 2018, compared with an income tax expense of $1.9 million in the second quarter of 2018 and an income tax expense of $2.5 million in the third quarter of 2017.

Net Income (Loss) and Earnings (Loss) per ADS

· Net loss attributable to Company's ordinary shareholders was $164.6 million in the third quarter of 2018, compared with net loss of $41.3 million in the second quarter of 2018 and net income of $5.0 million in the third quarter of 2017. Excluding certain one-time effects, net loss attributable to the Company's ordinary shareholders for the third quarter of 2018 was $39.7 million. Excluding these one-time effects as well as foreign exchange losses, net income attributable to Company's ordinary shareholders for the third quarter of 2018 was $2.7 million.
· Loss per fully diluted ADS on a GAAP basis was $1.98 in the third quarter of 2018, compared with a loss per fully diluted ADS of $0.50 in the second quarter of 2018 and income per fully diluted ADS of $0.06 in the third quarter of 2017. Excluding certain one-time effects, loss per fully diluted American Depositary Share for the third quarter of 2018 was $0.48. Excluding these one-time effects as well as foreign exchange losses, earnings per fully diluted American Depositary Share for the third quarter of 2018 was $0.03.

*2018 Third Quarter Financial Position*

As of September 30, 2018, the Company had cash and cash equivalents of $197.4 million, compared with $183.4 million as of December 31, 2017. The restricted cash as of September 30, 2018 was $140.2 million, compared with $139.7 million as of December 31, 2017.

As of September 30, 2018, accounts receivable was $554.8 million, compared with $525.4 million, as of December 31, 2017. Inventories were $498.4 million as of September 30, 2018, compared with $293.6 million as of December 31, 2017.

As of September 30, 2018, accounts payable was $665.9 million, compared with $454.8 million, as of December 31, 2017.

Total short-term borrowings (including the current portion of long-term borrowings) as of September 30, 2018 was $729.5 million, compared with $679.5 million as of December 31, 2017.

As of September 30, 2018, the Company had total long-term debt (net of current portion and long-term notes) of $625.5 million compared with $536.2 million as of December 31, 2017. The Company's long-term debt is comprised of bank and government borrowings, to be repaid in installments until their maturities, ranging from one to thirteen years.

Capital expenditures were $11.3 million in the third quarter of 2018.

*Operations Updates*

Production Capacity

As of September 30, 2018, the Company's in-house, annualized production capacities were 4,500 MW for cells and 4,500 MW for modules.

Furthermore, the Company has additional module availability of up to 3,900 MW (annualized) as of September 30, 2018 from Hanwha Q CELLS Korea Corporation, an affiliate of the Company. Hanwha Q CELLS Korea is expected to have a nameplate capacity of 1,700 MW of module capacity in the United States in the first quarter of 2019.

*Business Outlook*

Fourth Quarter and Full Year 2018 Guidance

For the fourth quarter of 2018, the Company estimates net revenues in the range of $590 to 610 million.

For the full year 2018, the Company provides the following guidance:

· Total module shipments in the range of 5,500 to 5,700 MW
· Capital expenditures of approximately $146.0 million for manufacturing technology upgrades and certain R&D related expenditures.

*About Hanwha Q CELLS *

Hanwha Q CELLS Co., Ltd. (NASDAQ: HQCL) is one of the world´s largest and most recognized photovoltaic manufacturers for its high-performance, high-quality solar cells and modules. It is headquartered in Seoul, South Korea (Global Executive HQ) and Thalheim, Germany (Technology & Innovation HQ) with its diverse international manufacturing facilities in Malaysia and China. Hanwha Q CELLS offers the full spectrum of photovoltaic products, applications and solutions, from modules to kits to systems to large-scale solar power plants. Through its growing global business network spanning Europe, North America, Asia, South America, Africa and the Middle East, the company provides excellent services and long-term partnerships to its customers in the utility, commercial, governmental and residential markets. Hanwha Q CELLS is a flagship company of Hanwha Group, a FORTUNE Global 500 firm and a Top 10 business enterprise in South Korea. For more information, visit: http://www.hanwha-qcells.com.

*Safe Harbor Statement*

This report contains forward-looking statements that are not statements of historical fact. These statements constitute "forward-looking" statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as "will,""expects,""anticipates,""future,""intends,""plans,""believes,""estimates" and similar statements. Such statements, particularly statements about our guidance for performance in the second quarter and the full year 2018, involve certain risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include pending administrative and civil actions in the United States under existing or potential new statutes and regulations governing trade between the United States and other countries, and potential antidumping, countervailing or other duties imposed on goods imported into the United States, as well as the Company's access to new capacity from an affiliate. Further information regarding these and other risks is included in Hanwha Q CELLS' filings with the Securities and Exchange Commission, including its annual report on Form 20-F. Except as required by law, Hanwha Q CELLS does not undertake any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.









*Hanwha Q CELLS Co., Ltd.* Unaudited Condensed Consolidated Balance Sheets (in millions of US dollars, except share data)











September 30,
2018


December 31,
2017

*ASSETS*




(unaudited)


(audited)

Current assets







Cash and cash equivalents


197.4


183.4


Restricted cash


140.2


139.7


Accounts and notes receivable - net


455.5


363.7


Receivables from related parties


99.3


161.7


Inventories



498.4


293.6


Derivative contracts


0.9


0.5


Other current assets


135.1


109.5


           Total current assets


1,526.8


1,252.1












Fixed assets - net


755.8


837.6


Intangible assets - net


30.0


32.0


Land use rights - net


31.3


49.0


Deferred tax assets - net


6.5


9.1


Loans to related parties


0.6


5.6


Other long-term assets


69.4


77.2


                Total assets


2,420.4


2,262.6

*LIABILITIES AND STOCKHOLDERS' EQUITY*




Current liabilities






Accounts payable


164.8


180.3


Notes payable


109.9


76.3


Payables to related parties


391.2


198.2


Deferred revenue


4.5


2.0


Accrued expenses


33.5


31.5


Other payables


24.1


23.1


Tax payables


11.9


9.2


Short-term debt


514.3


385.2


Current portion of long-term debt


115.3


294.3


Bonds payable - current portion


99.9


-


Customer deposits


17.5


10.4


Derivative contracts


0.6


0.4


Litigation accruals


0.1


0.2


Warranty provision


32.4


31.0


Other current liabilities


5.9


2.1


      Total current liabilities


1,525.9


1,244.2












Long-term debt


625.5


536.2


Long-term warranty provision


17.0


17.5


Deferred tax liabilities


5.3


8.7


     Total liabilities


2,173.7


1,806.6

Stockholders' equity






Ordinary shares


0.4


0.4


Additional paid-in capital


432.2


432.2


Accumulated income 


(80.0)


94.9


Accumulated other comprehensive loss


(105.9)


(71.5)


     Total stockholders' equity


246.7


456.0


     Total liabilities, redeemable ordinary shares and stockholders' equity

2,420.4


2,262.6

 











*Hanwha Q CELLS Co., Ltd.*

Unaudited Condensed Consolidated Statements of Operations and Comprehensive Income (Loss)

(in millions of US dollars, except share data and net income (loss) per share)

















For the three months ended 


For the nine months ended 



 September 30, 2018 


 June 30, 2018 


 March 31, 2018 


 September 30, 2018 


September 30, 2017



 (unaudited) 


 (unaudited) 


 (unaudited) 


  (unaudited)  


  (unaudited)   Net sales

559.3


518.4


443.0


1,520.7


1,552.7 Cost of goods sold

594.6


445.8


364.1


1,404.5


1,362.5            Gross profit

(35.3)


72.6


78.9


116.2


190.2 Selling and marketing expenses

37.5


42.0


28.6


108.1


82.0 General and administrative expenses

30.0


21.0


12.7


63.7


49.1 Research and development expenses

4.2


4.8


4.5


13.5


17.5 Other operating expenses (income)

-


-


-


-


(17.4)           Income (loss) from operations

(107.0)


4.8


33.1


(69.1)


59.0 Other income (expenses)









     Interest income

1.7


1.0


0.5


3.2


4.1      Interest expense

(15.8)


(16.2)


(12.7)


(44.7)


(32.8)      Foreign exchange gain (loss)

(42.4)


(37.8)


11.5


(68.7)


16.9      Gain (loss) on change in fair value of derivative contracts 

(0.9)


8.1


-


7.2


(4.0)      Investment income (loss)

0.6


0.4


0.7


1.7


1.7      Miscellaneous income (expense) - net

0.4


0.3


1.2


1.9


1.3      Other income (expenses), net

(56.4)


(44.2)


1.2


(99.4)


(12.8)           Income (loss) before income tax

(163.4)


(39.4)


34.3


(168.5)


46.2











Income tax expense (benefit)

1.2


1.9


3.3


6.4


4.9            Net income (loss)

(164.6)


(41.3)


31.0


(174.9)


41.3



































Net income (loss) attributable to Hanwha Q CELLS Co., Ltd.'s stockholders per share:






Basic



(US$0.04)


(US$0.01)


US$0.01


(US$0.04)


US$0.01 Diluted


(US$0.04)


(US$0.01)


US$0.01


(US$0.04)


US$0.01











Net income (loss) attributable to Hanwha Q CELLS Co., Ltd.'s stockholders per ADS:






Basic



(US$1.98)


(US$0.50)


US$0.37


(US$2.10)


US$0.50 Diluted


(US$1.98)


(US$0.50)


US$0.37


(US$2.10)


US$0.50











Number of shares used in computation of net income (loss) per share:








Basic



4,165,088,417


4,165,088,417


4,163,822,242


4,164,670,997


4,158,769,098 Diluted


4,165,088,417


4,165,088,417


4,163,822,242


4,164,670,997


4,158,769,098











Number of shares used in computation of net income (loss) per ADS:








Basic



83,301,768


83,301,768


83,276,445


83,293,420


83,175,382 Diluted


83,301,768


83,301,768


83,276,445


83,293,420


83,175,382











Other comprehensive income (loss)









     Foreign currency translation adjustment

(13.8)


(45.7)


25.1


(34.4)


51.3      Pension adjustments

-


-


-


-


- Comprehensive income (loss)

(178.4)


(87.0)


56.1


(209.3)


92.6

 

View original content:http://www.prnewswire.com/news-releases/hanwha-q-cells-reports-third-quarter-2018-results-300758143.html

Related Links :

http://www.hanwha-qcells.com Reported by PR Newswire Asia 2 hours ago.

EQS Group-News: u-blox AG / Key word(s): Corporate Action

30.11.2018 / 13:30
--------------------

*Credit Suisse shareholding announcement*

*Thalwil, Switzerland - November 30, 2018 -* u-blox (SIX:UBXN), a global provider of leading positioning and wireless communication technologies , today announced that Credit Suisse Group AG has communicated that as of 26 November 2018 it held directly or indirectly shareholdings of 11.17 %.

*About u-blox*

u-blox (SIX:UBXN) is a global provider of leading positioning and wireless communication technologies for the automotive, industrial, and consumer markets. Their solutions let people, vehicles, and machines determine their precise position and communicate wirelessly over cellular and short range networks. With a broad portfolio of chips, modules, and a growing ecosystem of products supporting data services, u-blox is uniquely positioned to empower its customers to develop innovative solutions for the Internet of Things, quickly and cost-effectively. With headquarters in Thalwil, Switzerland, the company is globally present with offices in Europe, Asia, and the USA.

Find us on Facebook, Google+, LinkedIn, Twitter @ublox and YouTube

*u‑blox contact:*
Gitte Jensen
Investor Relations
Phone +41 44 722 7486
gitte.jensen@u-blox.com

*u‑blox AG*
Zürcherstrasse 68
8800 Thalwil
Switzerland
Phone +41 44 722 74 44
Fax +41 44 722 74 47
info@u-blox.com
www.u‑blox.com

*Disclaimer*
This release contains certain forward-looking statements. Such forward-looking statements reflect the current views of management and are subject to known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements of the u-blox Group to differ materially from those expressed or implied. These include risks related to the success of and demand for the Group's products, the potential for the Group's products to become obsolete, the Group's ability to defend its intellectual property, the Group's ability to develop and commercialize new products in a timely manner, the dynamic and competitive environment in which the Group operates, the regulatory environment, changes in currency exchange rates, the Group's ability to generate revenues and profitability, and the Group's ability to realize its expansion projects in a timely manner. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described in this report. u-blox is providing the information in this release as of this date and does not undertake any obligation to update any forward-looking statements contained in it as a result of new information, future events or otherwise.
--------------------

End of Corporate News --------------------

Language: English
Company: u-blox AG
Zürcherstrasse 68
8800 Thalwil
Switzerland
Phone: +41 44 722 74 44
Fax: +41 44 722 74 47
E-mail: info@u-blox.com
Internet: www.u-blox.com
ISIN: CH0033361673
Listed: SIX Swiss Exchange
 
End of News EQS Group News Service Reported by EQS Group 2 hours ago.

In a joint press conference, European Council President Donald Tusk was noted saying that trade is more important than ever for Europe and there is no alternative to multilateralism, cooperation.

*Key quotes:*

   •  On way to reforming WTO is cooperation with the US.
   •  Nothing has changed between the EU and the US since July.
   •  We are discussing issues with the US.
   •  Made some progress on the Italian budget last weekend.
   •  Will meet PM Conte on Saturday.
   •  We are with Italy if Italy with us, the atmosphere is good. Reported by FXstreet.com 2 hours ago.

VANCOUVER, British Columbia, Nov. 30, 2018 (GLOBE NEWSWIRE) -- *Isodiol International Inc. *(*CSE*: *ISOL*) (*OTCQB*:* ISOLF*) (*FSE: LB6B.F*)* (the “Company” or “Isodiol”)* announces its financial and operational results for the second quarter of fiscal 2019, ended September 30, 2018.   Second Quarter Highlights include:

· Total Revenue of $8,030,825 with gross profit of $4,317,612.
· The Company was included as a show segment on the national *PBS series “American Health Journal – Innovations in Medicine.”*
· *Iso-Sport* (subsidiary of the Company) entered into *an agreement with Altis LLC* to create the “Iso-Sport Living Lab.”
· The Company announced the appointment of *Marvin Washington to its Board of Directors.*
· The Company entered into an *agreement with Powerhouse Gym* to be the preferred vendor of CBD performance products offered to its gym members.

Subsequent Events:

· Iso-Sport (subsidiary of the Company) *reached deals with London Fight Store, and Grapplestore*, two UK based mixed martial arts retailers, to sell the CBD Performance Products.
· The Company executed *an agreement with Brew Hub, LLC* for the exclusive development and manufacturing of its hemp, cannabis, hemp-derived, and cannabis-derived beverages.
· The Company entered into *an agreement with Record Street Brewing Co* for R&D of hemp-based beers and functional beverages.
· On November 21, 2018 the Company announced the appointment of *Leonardo Matesanz to it’s Board of Directors.*

“In anticipation of the US Farm bill being finalized,^1 and with the possibility of an increase in demand for consumer packaged goods (CPG), the Company scaled back bulk raw ingredient CBD sales in an effort to increase production and inventory of CPG for 2019,” said CEO of Isodiol, Marcos Agramont.  “While this has impacted our Q2 revenues, the Company believes this move was necessary for long-term, sustainable growth.”

The unaudited condensed consolidated interim financial Statements and MD&A for the three months ended September 30, 2018 will be filed on SEDAR and available at *www.sedar.com*.

______________________________

^1https://www.reuters.com/article/us-usa-farmbill/farm-bill-deal-very-close-senators-say-idUSKCN1NX2ON 

*About Isodiol International Inc.*

*Isodiol International Inc.* is focused on the nutritional health benefits that are derived from hemp and is a product development, sales, marketing and distribution company of hemp-based consumer products and solutions.

Isodiol has commercialized a 99%+ pure, naturally isolated CBD, including micro-encapsulations, and nano-technology for quality consumable and topical skin care products. Most recently, the Company received approval for its CBD designated as an Active Pharmaceutical Ingredient for use in Finished Pharmaceutical Products, as was announced on April 26, 2018.

Isodiol’s growth strategy includes the development of over-the-counter and pharmaceutical drugs and continued international expansion into Latin America, Asia, and Europe.

*Join Us On Facebook*: https://www.facebook.com/IsodiolInternationalInc/
*Twitter:* @Isodiolintlinc

*ON BEHALF OF THE BOARD*
Marcos Agramont, CEO & Director

*INVESTOR RELATIONS:*
Ir@isodiol.com
*604-409-4409*

*MEDIA CONTACT:*
Christopher Hussey
media@isodiol.com*Forward-Looking Information:* This news release contains "forward-looking information" within the meaning of applicable securities laws relating to statements regarding the Company's business, products and future of the Company’s business, its product offerings and plans for sales and marketing. Although the Company believes that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. Readers are cautioned not to place undue reliance on forward-looking information. Such forward-looking statements are subject to risks and uncertainties that may cause actual results, performance and developments to differ materially from those contemplated by these statements depending on, among other things, the risks that the Company's products and plan will vary from those stated in this news release and the Company may not be able to carry out its business plans as expected. Except as required by law, the Company expressly disclaims any obligation and does not intend, to update any forward-looking statements or forward-looking information in this news release. Although the Company believes that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct and makes no reference to profitability based on sales reported. The statements in this news release are made as of the date of this release.

The CSE has not reviewed, approved or disapproved the content of this press release. Reported by GlobeNewswire 41 minutes ago.

DGAP-News: Aves One AG / Key word(s): Change of Personnel

30.11.2018 / 14:00
The issuer is solely responsible for the content of this announcement.
--------------------

*Expansion of the Management Board of Aves One AG*Hamburg, 30 November 2018 - At its meeting held yesterday, the Supervisory Board of Aves One AG decided to appoint Mr. Tobias Aulich to a further Member of the Management Board for four years with immediate effect. Mr. Aulich (36 years) complements the Management Team of Jürgen Bauer and Sven Meißner.

Tobias Aulich has worked for the Aves One Group for a period of five years. As the managing director of several subsidiaries Mr. Aulich played an important role in the significant expansion of the logistic portfolio paving the way for the strong operative growth of the company. He has profound and long-standing experience in the fields of acquisitions, financing and portfolio management.

Ralf Wohltmann, Head of the Supervisory Board of Aves One AG: "We are pleased that Mr. Aulich will complement our management team. He will contribute in-depth knowledge about our core markets and the corresponding processes. The strengthening of our management team is a necessary and consistent step after the recent considerable growth of the company and in order to be well-prepared for the future."

*About Aves One AG*

Aves One AG is a strongly expanding holder of long-life logistics assets with a focus on freight cars. The portfolio also includes containers and swap bodies. The company plans to increase the value of its assets to more than EUR 1 billion by the end of 2019. With a young, profitable freight car portfolio, Aves One is one of the leading holders of rail logistics assets in Europe. The strategy is geared to constant optimisation of Aves One's stock and further expansion of the logistics portfolio. Based in Hamburg, Aves One AG is listed on the regulated market (Prime Standard) of the Frankfurt Stock Exchange (ISIN: DE000A168114; WKN: A16811).

*For further information*
www.avesone.com*Contact*
Aves One AG
Jürgen Bauer, Management Board
T +49 (40) 696 528 350
F +49 (40) 696 528 359
E ir@avesone.com
--------------------

30.11.2018 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de --------------------

Language: English
Company: Aves One AG
Große Elbstrasse 61
22767 Hamburg
Germany
Phone: 040 696528 350
Fax: 040 696528 359
E-mail: ir@avesone.com
Internet: www.avesone.com
ISIN: DE000A168114
WKN: A16811
Listed: Regulated Market in Frankfurt (Prime Standard), Hamburg, Hanover; Regulated Unofficial Market in Berlin, Dusseldorf, Stuttgart; London
 
End of News DGAP News Service Reported by EQS Group 1 hour ago.

Car stocks and miners drag Europe down as weak China data and trade fears sap confidence Reported by euronews 1 hour ago.

SEATTLE, Nov. 30, 2018 (GLOBE NEWSWIRE) -- According to Coherent Market Insights, the global automotive premium audio system market was valued at US$ 98.5 million in 2017 and is projected to exhibit a CAGR of 2.7% over the forecast period (2018 – 2026).

*To know the latest trends and insights prevalent in this market, click the link below:*

*https://www.coherentmarketinsights.com/market-insight/automotive-premium-audio-system-market-2318*

*Key trends and analysis of the global automotive premium audio system market:*

Increasing production of vehicles is one of the major factors driving growth of the market. For instance, according to the Organization Internationale des Constructeurs Automobiles (OICA), the total number of vehicles produced in 2016 was 95 million units, which increased to 97 million units in 2017 worldwide. Increasing production of vehicles leads to high demand for premium audio system that offer high-quality sound. Moreover, premium audio systems can be voice-controlled and can be operated via smartphone. Therefore, these factors are expected to propel growth of the global automotive premium audio system market.

*Request Sample Copy of this Report*

*Key Market Takeaways:*

· The global automotive premium audio system market is projected to witness CAGR of 2.7% during the forecast period, owing to increasing sales of vehicles worldwide
· Europe is expected to witness significant growth in the global automotive premium audio system market followed by North America. This is due to increasing demand for vehicles in countries such as Germany and the U.K. For instance, according to OICA, sales or new registrations of vehicles in Europe was around 20.9 million units in 2017, which increased from 20.1 million units in 2016. Moreover, presence of key players, especially in Germany and the U.K., is also expected to accelerate growth of the automotive premium audio system market in Europe.
· On the basis of application, passenger cars segment accounted for the highest market share in 2017 and is expected to retain its market position over the forecast period, owing to increasing sales of passenger cars. For instance, according to OICA’s analysis, sales of passenger cars in 2016 was 69.5 million units and increased to 70.8 million units in 2017, worldwide. This factor proportionally increase the equipment of premium audio system in the passenger cars over forecasted period.
· Major players operating in the global automotive premium audio system market include, Bose Corporation, Bowers & Wilkins, Harman International Industries, Inc., Klipsch Audio Technologies, Bang & Olufsen, Alpine Electronics, Inc., Sonos, Onkyo Corporation, Panasonic Automotive System, Blaupunkt GmbH, and QSC, LLC.

CONTACT: Contact Us:
Mr. Shah
Coherent Market Insights
1001 4th Ave.
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com Reported by GlobeNewswire 41 minutes ago.

Two recent reports suggest homophobia remains a major issue in sport, both in Germany and across Europe. But is that always the case? And what is being done about it? DW takes a look at the state of play. Reported by Deutsche Welle 1 hour ago.

According to the report, the global cyber security in healthcare market was valued at approximately USD 6.6 billion in 2017 and is expected to generate revenue of around USD 10.7 billion by the end of 2024, growing at a CAGR of around 7.1% between 2018 and 2024.

New York, NY, Nov. 30, 2018 (GLOBE NEWSWIRE) -- Zion Market Research  has published a new report titled *“Cyber Security in Healthcare Market by Deployment (On-Premise and Cloud-Based), by Security Type (Application Security, Cloud Security, Content Security, Endpoint Security, Network Security, and Wireless Security), and by End-User (Pharmaceutical & Chemical Manufactures, Medical Device Companies, Health Insurance Companies, Hospitals & Clinics, and Others): Global Industry Perspective, Comprehensive Analysis, and Forecast, 2017 – 2024”*. According to the report, the global cyber security in healthcare market was valued at approximately USD 6.6 billion in 2017 and is expected to generate revenue of around USD 10.7 billion by the end of 2024, growing at a CAGR of around 7.1% between 2018 and 2024.

Cyber security refers to the protection of internet-connected systems, including hardware, software, and data, from cyber-attacks.  All the data, including electronic records and patient records, available on any device are a target for cyber-attacks. Data breach is a major concern, as several instances of data thefts and data breach have occurred since the introduction of connected medical devices technology. In the U.S., FDA’s recently released final guidance on the post-market management of cyber security in medical devices is a part of the FDA’s constant efforts to ensure safety and efficacy of medical devices, as they encounter cyber threats, at all stages in the devices’ lifecycle. Healthcare is vulnerable due to the historic lack of investments for cyber security, vulnerabilities in existing technology, and staff behavior. It has become increasingly clear that cyber security is a risk factor for healthcare data. Attacks can compromise not only networks and data but also threaten applications and services supporting critical patient care systems.

*Browse through 54 Tables & 31 Figures spread over 110 Pages and in-depth TOC on “Global Cyber Security in Healthcare Market Size, Share 2017: Industry Trends, Growth Analysis and Forecast, 2024”.*

*Request Free Sample Report of Global Cyber Security In Healthcare Market Report @ *https://www.zionmarketresearch.com/sample/cyber-security-healthcare-market

Major factors driving the growth of cyber security in healthcare market are an increase in cyber-attacks, increased use of laptops, mobiles, and smartphones with healthcare applications, and the introduction of advanced technology solutions. Moreover, an increase in the number of government regulations and increased focus on IT and its use in healthcare are anticipated to gain traction in the forecast period. Furthermore, increased use of cloud services in hospitals to maintain and provide quick access to patient records are also projected to promote the growth of cyber security in healthcare market. Cloud services offer advanced technical solutions at a reasonable price as compared to on-premise hardware and software, but security and privacy issues related to the implementation of such paradigms should not be undermined. According to a recent study, the installed base of such interconnected medical devices accounted around USD 17.5 Billion, in 2016. However, lack of awareness and shortage of trained professionals might hamper the growth of cyber security in healthcare market.

The cyber security in healthcare market is bifurcated on the basis of deployment into on-premise and cloud-based. The cloud-based segment is anticipated to experience a significant growth rate in the forecast timeframe. The security type segment is divided into application security, cloud security, content security, endpoint security, network security, and wireless security. Cloud security segment is anticipated to experience significant growth in the forecast timeframe. The end-user segment is divided into pharmaceutical and chemical manufacturers, medical device companies, health insurance companies, hospitals and clinics, and others. Hospitals and Clinics segment is expected to experience a significant growth rate in the forecast timeframe.

*Download Free Report PDF Brochure: *https://www.zionmarketresearch.com/requestbrochure/cyber-security-healthcare-market

North America and Europe are anticipated to be the leading regions for cyber security in healthcare market globally. North America held major market share and accounted for around 40% revenue share in 2015. The presence of advanced healthcare infrastructure in developed countries, such as the U.S. and Canada, is fuelling this region’s market growth. Furthermore, huge investments related to IT infrastructure, research and development activities, increase in the awareness among people, and increased use of cloud services are expected to promote the growth of cyber security in healthcare market in the upcoming years.

Asia Pacific is projected to showcase a high growth rate in the cyber security in healthcare market and grow at the higher CAGR as compared to other regions. Increased awareness in countries like India, China, and Japan has majorly impacted the growth of cyber security in healthcare market in this region. Moreover, rising aging population, large patient pool, and rising healthcare infrastructure due to initiatives were taken by the government and private companies to promote and increase the use of IT in healthcare are also driving the growth for cyber security in healthcare market in this region.

Browse the full *"Cyber Security in Healthcare Market by Deployment (On-Premise and Cloud-Based), by Security Type (Application Security, Cloud Security, Content Security, Endpoint Security, Network Security, and Wireless Security), and by End-User (Pharmaceutical & Chemical Manufactures, Medical Device Companies, Health Insurance Companies, Hospitals & Clinics, and Others): Global Industry Perspective, Comprehensive Analysis, and Forecast, 2017 – 2024"* report at https://www.zionmarketresearch.com/report/cyber-security-healthcare-market

The Middle East and Africa and Latin America are also likely to be potential markets for cyber security in healthcare, owing to the opportunities provided by the government to companies to increase awareness among people and discover the untapped areas of IT in healthcare for improved patient health in these regions.

Some leading players of the global cyber security in healthcare market include Symantec Corporation, Sensato Cybersecurity Solutions, ForgeRock, Inc., Northrop Grumman Corporation, Lockheed Martin Corporation, WhiteHat Security, Inc., Palo Alto Networks, Inc., AO Kaspersky Lab, IBM Corporation, Trend Micro Incorporated, Trend Micro Incorporated, Axway, CORL Technologies, FireEye, Inc., Flexera, Cisco Systems, Inc., Biscom, Inc., Computer Sciences Corporation, Booz Allen Hamilton, Inc., and McAfee LLC.

*Request customized copy of report @ *https://www.zionmarketresearch.com/custom/3505

*This report segments the global cyber security in healthcare market as follows:*

*Global Cyber Security in Healthcare Market: Deployment Segment Analysis*

· On-Premise
· Cloud-Based

*Global Cyber Security in Healthcare Market: Security Type Segment Analysis*

· Application Security
· Cloud Security
· Content Security
· Endpoint Security
· Network Security
· Wireless Security

*Global Cyber Security in Healthcare Market: End-User Segment Analysis*

· Pharmaceutical & Chemical Manufactures
· Medical Device Companies
· Health Insurance Companies
· Hospitals & Clinics
· Others (Research Institutes, Cell Banks, etc.)

*Global Cyber Security in Healthcare Market: Regional Segment Analysis*

· North America

· The U.S.

· Europe

· UK
· France
· Germany

· Asia Pacific

· China
· Japan
· India

· Latin America

· Brazil

· The Middle East and Africa

*Related Reports:*

· *Blockchain in Retail Market:* https://www.zionmarketresearch.com/report/blockchain-retail-market
· *Dashboard Software Market:* https://www.zionmarketresearch.com/report/dashboard-software-market
· *Intelligent Apps Market:* https://www.zionmarketresearch.com/report/intelligent-apps-market
· *Customer Engagement Solutions Market: *https://www.zionmarketresearch.com/report/customer-engagement-solutions-market
· *Artificial Intelligence (AI) In Supply Chain Market: *https://www.zionmarketresearch.com/report/artificial-intelligence-in-supply-chain-market      

*About Us:*

Zion Market Research is an obligated company. We create futuristic, cutting edge, informative reports ranging from industry reports, company reports to country reports. We provide our clients not only with market statistics unveiled by avowed private publishers and public organizations but also with vogue and newest industry reports along with pre-eminent and niche company profiles. Our database of market research reports comprises a wide variety of reports from cardinal industries. Our database is been updated constantly in order to fulfill our clients with prompt and direct online access to our database. Keeping in mind the client’s needs, we have included expert insights on global industries, products, and market trends in this database. Last but not the least, we make it our duty to ensure the success of clients connected to us—after all—if you do well, a little of the light shines on us.

*Follow Us LinkedIn: *https://www.linkedin.com/company/zion-market-research
*Follow Us Twitter: *https://twitter.com/zion_research

*Blog:* http://www.intenseresearch.com | http://www.mrsresearchgroup.com | http://www.marketresearchtrade.com | https://qyresearchgroup.com | http://marketnreports.com | https://zmrnewsjournal.us | http://www.e-marketresearch.com

*Contact Us:*

Joel John
244 Fifth Avenue, Suite N202
New York, 10001, United States
Tel: +49-322 210 92714
USA/Canada Toll-Free No.1-855-465-4651
*Email:* sales@zionmarketresearch.com

*Website:* https://www.zionmarketresearch.com

*Blog:* http://zmrblog.com Reported by GlobeNewswire 41 minutes ago.

Dublin, Nov. 30, 2018 (GLOBE NEWSWIRE) -- The "Global Continuous Renal Replacement Therapy (CRRT) Market Analysis & Trends - Industry Forecast to 2027" report has been added to *ResearchAndMarkets.com's* offering.The Global Continuous Renal Replacement Therapy (CRRT) Market is poised to grow strong during the forecast period 2017 to 2027.

Some of the prominent trends that the market is witnessing include increasing prevalence of diabetes and hypertension and development of CRRT system for pediatric patients.

This industry report analyzes the market estimates and forecasts of all the given segments on global as well as regional levels presented in the research scope. The study provides historical market data for 2015, 2016 revenue estimations are presented for 2017 and forecasts from 2018 till 2027.

The study focuses on market trends, leading players, supply chain trends, technological innovations, key developments, and future strategies. With comprehensive market assessment across the major geographies such as North America, Europe, Asia Pacific, Middle East, Latin America and Rest of the world the report is a valuable asset for the existing players, new entrants and the future investors.

The study presents detailed market analysis with inputs derived from industry professionals across the value chain. A special focus has been made on 23 countries such as U.S., Canada, Mexico, U.K., Germany, Spain, France, Italy, China, Brazil, Saudi Arabia, South Africa, etc.

The market data is gathered from extensive primary interviews and secondary research. The market size is calculated based on the revenue generated through sales from all the given segments and sub segments in the research scope. The market sizing analysis includes both top-down and bottom-up approaches for data validation and accuracy measures.

*Report Highlights*

· The report provides a detailed analysis on current and future market trends to identify the investment opportunities
· Market forecasts till 2027, using estimated market values as the base numbers
· Key market trends across the business segments, Regions and Countries
· Key developments and strategies observed in the market
· Market Dynamics such as Drivers, Restraints, Opportunities and other trends
· In-depth company profiles of key players and upcoming prominent players
· Growth prospects among the emerging nations through 2027
· Market opportunities and recommendations for new investments

*Key Topics Covered*

1 Market Outline
1.1 Research Methodology
1.2 Market Trends
1.3 Regulatory Factors
1.4 Product Analysis
1.5 End User Analysis
1.6 Strategic Benchmarking
1.7 Opportunity Analysis

2 Executive Summary

3 Market Overview
3.1 Current Trends
3.1.1 Increasing Prevalence of Diabetes and Hypertension
3.1.2 Development of CRRT System for Pediatric Patients
3.1.3 Recent Technological Developments in Continuous Renal Replacement Therapy
3.1.4 Growth Opportunities/Investment Opportunities
3.2 Drivers
3.3 Constraints
3.4 Industry Attractiveness

4 Continuous Renal Replacement Therapy (CRRT) Market, By Product
4.1 Dialysates And Replacement Fluids
4.2 Systems
4.3 Disposables

5 Continuous Renal Replacement Therapy (CRRT) Market, By Modality
5.1 Continuous Venovenous Hemodiafiltration (CVVHDF)
5.2 Continuous Venovenous Hemofiltration (CVVH)
5.3 Continuous Venovenous Hemodialysis (CVVHD)
5.4 Slow continuous ultra filtration (SCUF)

6 Continuous Renal Replacement Therapy (CRRT) Market, By Therapy
6.1 Non-renal
6.2 Renal
6.3 Combination of Both (Renal and Non- Renal)

7 Continuous Renal Replacement Therapy (CRRT) Market, By End-user
7.1 Clinics
7.2 Hospitals
7.3 Homes

8 Continuous Renal Replacement Therapy (CRRT) Market, By Geography
8.1 North America
8.2 Europe
8.3 Asia Pacific
8.4 Middle East
8.5 Latin America
8.6 Rest of the World (RoW)

9 Key Player Activities
9.1 Acquisitions & Mergers
9.2 Agreements, Partnerships, Collaborations and Joint Ventures
9.3 Product Launch & Expansions
9.4 Other Activities

10 Leading Companies
10.1 Baxter International Inc.
10.2 Infomed SA
10.3 Medtronic PLC
10.4 Bellco S.R.L.
10.5 Medica S.P.A.
10.6 Ningbo Tianyi Medical Appliance Co. Ltd.
10.7 Toray Medical Company Limited
10.8 Fresenius Medical Care AG & Co. KGaA
10.9 B. Braun Melsungen AG
10.10 SWS Hemodialysis Care Co. Ltd.
10.11 Medites Pharma Spol. S.R.O.
10.12 Toray Medical Co., Ltd,
10.13 Medical Components, Inc.,
10.14 Central Admixture Pharmacy Services Inc.
10.15 Jihua Medical Apparatus & Instruments Co.

For more information about this report visit https://www.researchandmarkets.com/research/bz4w89/2018_continuous?w=12

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

CONTACT:
CONTACT: ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Liver and Kidney Disorders Drugs Reported by GlobeNewswire 41 minutes ago.

According to the report, the global textile chemical market was valued at around USD 2500 million in 2017 and is expected to reach approximately USD 3160 million by 2024, growing at a CAGR of slightly above 4.5% between 2018 and 2024.

New York, NY, Nov. 30, 2018 (GLOBE NEWSWIRE) -- Zion Market Research has published a new report titled *“Textile Chemicals Market by Fiber (Natural, Synthetic), by Product Type (Coating & Sizing, Colorants & Auxiliaries, Finishing Agents, Desizing Agents, Surfactants, Bleaching Agents, and Others), and by Application (Apparels, Home Textile, Technical Textile, and Others): Global Industry Perspective, Comprehensive Analysis, and Forecast, 2017-2024’’*. According to the report, the global textile chemical market was valued at around USD 2500 million in 2017 and is expected to reach approximately USD 3160 million by 2024, growing at a CAGR of slightly above 4.5% between 2018 and 2024.

The textile industry can also be termed as a chemical dependent industry, as it utilizes a variety of chemicals during the manufacturing process. Textile chemicals include a huge range of products, such as surfactants, starch, sulfonated oils, and grease, among various other products. These chemicals are largely used for applications in pre-treatment processes, like coatings, sizing, etc.

*Browse through 81 Tables & 30 Figures spread over 115 Pages and in-depth TOC on “Global Textile Chemicals Market: Type, Application, Industry Size, Trends, Share and Forecast, 2017 – 2024”.*

*Request Free Sample Report of Global Textile Chemicals Market Report @* https://www.zionmarketresearch.com/sample/textile-chemicals-market

Growing industrialization across different countries, such as China, India, etc., is the major reason for improved sales of the textile chemicals market in the last few years. China is one of the largest producers of textile chemicals around the globe. The country has large domestic consumption of textile chemicals and also exports huge volumes of materials to Japan, Europe, and America. On the other hand, India also has a massive market for textile chemicals and has its domestic production and exports of materials like cotton, synthetic fibers, and others. The increase in the disposable income has helped the country in supporting the growth of this market. The demand for technical textile is rapidly increasing. These textiles are largely favored in industries where there is a demand for superior properties and functionality. Automotive, construction, packaging, and healthcare industries are some of the major contributors to the growth of this market. The technical textile market is anticipated to have a market value of approximately USD 950 million by 2025. The coating and sizing chemicals are one of the most-used products for the textile chemicals market. However, stringent environmental regulations regarding the disposal of textile effluents are acting as a key restraining factor for this market. Nevertheless, increasing demand for technical textile is anticipated to provide new opportunities for the major players of the global textile chemicals market.

The global textile chemicals market is diversified based on product type, application, and fiber type. By product type, the market for global textile chemicals is divided into colorant & auxiliaries, bleaching agent, finishing agents, surfactants, coating & sizing agents, desizing agents, and others. By application, the market is classified into apparels, home textile, technical textile, and others. The apparels are further divided into sportswear, intimates, and outerwear. The home textile is sub-segmented into bed linens, carpets, curtains, and others. By fiber type, the market is bifurcated into the natural and synthetic fiber. The natural fiber is further segmented into cotton, wool, and others. The synthetic fiber is sub-segmented into polyester, polyamide, viscose, and others. 

*Download Free Report PDF Brochure: *https://www.zionmarketresearch.com/requestbrochure/textile-chemicals-market

The apparel segment is anticipated to be the major end-user of the global textile chemicals market and is anticipated to grow at a high growth rate over the forecast period. Moreover, rapid urbanization in the Asia Pacific is also anticipated to increase the demand for the textile chemicals market.

The regional segmentation of the textile chemicals market includes Europe, Asia Pacific, North America, Latin America, and the Middle East and Africa. Asia Pacific region is expected to have the highest market growth in the future. This can be attributed to the high supply and demand of the textile chemicals in the region. Countries like China and India have a huge consumer base for apparels market. China is listed among the top countries for textile chemicals’ consumption and is expected to witness a huge growth rate in the years to come. Moreover, increasing disposable income in the region has further helped in improving the demand for textile chemicals in the region. The availability of cheap labor and raw material in the region has resulted in the region now holding around 60% of the global textile chemicals market.

Browse the full *"Textile Chemicals Market by Fiber (Natural, Synthetic), by Product Type (Coating & Sizing, Colorants & Auxiliaries, Finishing Agents, Desizing Agents, Surfactants, Bleaching Agents, and Others), and by Application (Apparels, Home Textile, Technical Textile, and Others): Global Industry Perspective, Comprehensive Analysis, and Forecast, 2017-2024"* report at https://www.zionmarketresearch.com/report/textile-chemicals-market

North America is another key region for the textile chemicals market and is likely to witness a high growth rate in the future, due to the growing textile industries in the region. Moreover, various technological advances happening across the region are further driving the growth of this market. The different key players in the region are focusing on new technological developments to support the growth of the market for textile chemicals in the region. The apparels industry is the dominating industry in the region, which is further boosting the growth of the textile chemicals market in North America.

Europe is likely to witness sluggish growth in the textile chemicals market in the forecast timeframe. The apparels market is expected to be the most dominant end-user in the European region, which, in turn, will increase the usage of textile chemicals in the region as well. The technological developments in the market are also anticipated to further support this market’s growth. The European Union has implemented integrated Pollution Prevention and Control Directive in order to restrict the usage of harmful chemicals that might have a negative effect on the overall growth of the textile chemicals market in this region.

*Request for The Discount on This Report: *https://www.zionmarketresearch.com/requestdiscount/textile-chemicals-market

Some key players operating in the global textile chemicals market includeArchroma, Tanatex Chemicals, Huntsman, Dowdupont, Evonik Industries, WackerChemie AG, Rudolf Group, Bozzetto Group, Dystar Group, and AkzoNobel N.V., among others.

*Request customized copy of report @* https://www.zionmarketresearch.com/custom/289

*This report segments the global textile chemicals market as follows:*

*Textile Chemicals Market: Fiber Type Segment Analysis*

· Natural Fiber 

· Cotton
· Wool
· Others

· Synthetic Fiber 

· Polyester
· Polyamide
· Viscose
· Others

*Textile Chemicals Market: Product Type Segment Analysis*

· Coating & Sizing Agents 
· Colorant & Auxiliaries 
· Finishing Agents 
· Surfactants
· Desizing Agents 
· Bleaching Agents 
· Others

*Textile Chemicals Market: Application Segment Analysis*

· Apparels

· Sportswear
· Intimates
· Outerwear

· Home Textile

· Bed Linens
· Carpet
· Curtains
· Others

· Technical Textile
· Others

*Textile Chemicals Market: Regional Segment Analysis*

· North America

· The U.S.

· Europe

· UK
· France
· Germany

· Asia Pacific

· China
· Japan
· India

· Latin America

· Brazil

· The Middle East and Africa

*Related Reports:*

· *Biodegradable Plastics Market: *https://www.zionmarketresearch.com/report/biodegradable-plastics-market
· *Construction Fabrics Market:* https://www.zionmarketresearch.com/report/construction-fabrics-market
· *Adhesives Films Market:* https://www.zionmarketresearch.com/report/adhesives-films-market
· *3D Printing Plastics Market:* https://www.zionmarketresearch.com/report/3d-printing-plastics-market
· *Composite Coatings Market:* https://www.zionmarketresearch.com/report/composite-coatings-market     

*About Us:*

Zion Market Research is an obligated company. We create futuristic, cutting-edge, informative reports ranging from industry reports, company reports to country reports. We provide our clients not only with market statistics unveiled by avowed private publishers and public organizations but also with vogue and newest industry reports along with pre-eminent and niche company profiles. Our database of market research reports comprises a wide variety of reports from cardinal industries. Our database is been updated constantly in order to fulfill our clients with prompt and direct online access to our database. Keeping in mind the client’s needs, we have included expert insights on global industries, products, and market trends in this database. Last but not the least, we make it our duty to ensure the success of clients connected to us—after all—if you do well, a little of the light shines on us.

*Follow Us LinkedIn: *https://www.linkedin.com/company/zion-market-research
*Follow Us Twitter: *https://twitter.com/zion_research

*Blog:* http://www.intenseresearch.com | http://www.mrsresearchgroup.com | http://www.marketresearchtrade.com | https://qyresearchgroup.com | http://marketnreports.com | https://zmrnewsjournal.us | http://www.e-marketresearch.com

*Contact Us:*

Joel John
244 Fifth Avenue, Suite N202
New York, 10001, United States
Tel: +49-322 210 92714
USA/Canada Toll-Free No.1-855-465-4651
*Email:* sales@zionmarketresearch.com

*Website:* https://www.zionmarketresearch.com

*Blog:* http://zmrblog.com Reported by GlobeNewswire 41 minutes ago.

Today, 30 November, the unaudited condensed consolidated interim financial statements of Latvenergo Group for the nine months of 2018 are published. In the nine months of 2018, Latvenergo Group's revenue amounts to EUR 642.0 million, which is 5% less than in the same period last year. EBITDA of the Group is EUR 270.2 million, which is 10% less than in the previous year. The amount of electricity generated by the Group has remained at the prior year's level and reached 4,052 GWh (gigawatt hours). The Riga CHPPs have played an indispensable role in the reporting period, as generation at the Riga CHPPs was able to make up for the demand for electricity during the prolonged downtime of the Nordbalt cable. In October 2018, the Group started natural gas trade in Lithuania, which means that Latvenergo operates in all market segments in Latvia, Lithuania and Estonia.

Riga, 2018-11-30 14:30 CET (GLOBE NEWSWIRE) -- The 9 months of 2018 are characterised by a significant and unexpected increase in electricity prices across Europe, particularly in the Nordic countries. The price of electricity at the electricity exchange NordPool increased by 47% on average, and in the Baltics prices increased by almost 40% (38% in Latvia), compared to the corresponding period last year. This was mainly due to the dry and warm weather throughout Europe, lower water levels at the Scandinavian hydropower reservoirs, smaller output at wind farms as well as rising prices of CO2 emission allowances and raw materials. In these circumstances, the role of the Riga CHPPs in the market was particularly important. If the Riga CHPPs were not available for generation in Latvia, we would have to use higher-cost electricity generation sources to satisfy the demand, such as a lower-efficiency gas plant in Lithuania, coal plants in Poland or other capacities designed to ensure the stability of the power system.

Due to an efficient response to the situation in the electricity market, the electricity output by the Riga CHPPs in the reporting period is 71% higher than last year and amounts to 1,844 GWh. In turn, the amount of electricity generated by the Daugava HPPs decreased by 27% compared to the same period last year and amounts to 2,170 GWh. The reduction of the output at the Daugava HPPs was affected by lower water inflow in the river Daugava compared to last year. More than half of the Group's total electricity output of 4,052 GWh was generated from renewable energy sources.

The amount of thermal energy generated in the nine months of 2018 is 14% less compared to the same period last year reaching 1,545 GWh. The decrease was influenced by increasing competition with new heat generators in the Riga thermal energy market.

In the reporting period, a total of 5 TWh of electricity was sold to Baltic retail customers. Approximately 1/3 of the total retail electricity trade or 1.8 TWh was sold to customers outside Latvia. In October, we also started natural gas trade in Lithuania, thus we are already operating in all segments of the market in Latvia, Lithuania and Estonia. The natural gas sales of Latvenergo Group and the number of customers continued to grow in the reporting period. As of the end of the reporting period, the total number of natural gas customers exceeds 300. In the reporting period, the amount of natural gas used for both operating consumption and trade reached 4.8 TWh.

In line with the strategic goals of the Group to offer new products and services, retail sales activities involving additional products continued in the Baltic states during the reporting period. In Q3 2018, the trade of Elektrum Solārais (Elektrum Solar) was launched in Estonia. In the reporting period, solar panels were installed for about 50 customers in the Baltics. The number of Elektrum Apdrošināts (Elektrum Insured) customers also continues to grow and by the end of the reporting period it reached more than 36 thousand.

Latvenergo Group’s revenue in the nine months of 2018 decreased by 5% and amounts to EUR 642.0 million. EBITDA decreased by 10%, reaching EUR 270.2 million. The Group’s profit amounts to EUR 83.1 million. The results were negatively impacted by smaller electricity generation at the Daugava HPPs and higher prices of electricity and CO2 emission allowances.

In the nine months of 2018, the total amount of Latvenergo Group’s investments decreased by 5% compared to the corresponding period last year and reached EUR 158.5 million. 80% of overall investments was made in the modernisation of the power networks in order to ensure a higher level of quality and security of the services. EUR 16.9 million was invested in the reconstruction of hydropower units of Daugava HPPs, which will ensure their operation for the next 40 years. The investments in the Kurzeme Ring project, which significantly increases the security of energy supply in Kurzeme region and Latvia as a whole, amounted to EUR 184.6 million by the end of the reporting period, while the reconstruction of substations and construction works continued in several 330 kV transmission lines. The Third Estonia–Latvia power transmission network interconnection project continues as well. This project is of major significance for the future electricity transmission infrastructure of the whole Baltic region.

Shortly after the end of the reporting period, on 10 October, Latvenergo AS received the most valuable Latvian company award within TOP 101 Most Valuable Companies of Latvia, jointly created by Prudentia and Nasdaq Riga, for the 11^th time in total and for the 10^th time in a row. The Group also maintained its leading position among the Baltic states, ranking third on the list of TOP 10 Baltic Most Valuable Enterprises, ahead of the energy companies from Estonia and Lithuania.

The unaudited condensed consolidated interim financial statements of Latvenergo Group for 2018 will be published on 28 February 2019. 

 

*Latvenergo Group’s Key Performance Indicators*

Operational Figures

    *9M 2018* *9M 2017*
Electricity supply GWh 7,476 7,646
Retail* GWh 5,029 5,189
Wholesale** GWh 2,447 2,457
Natural gas supply GWh 74 8
Electricity generated GWh 4,052 4,088
Thermal energy generated GWh 1,545 1,791
Number of employees   3,521 4,053
Moody's credit rating   Baa2 (stable) Baa2 (stable)

*   Including operating consumption

** Including sale of energy purchased within the mandatory procurement on the Nord Pool

 

Financial Figures

EUR’000

  *9M 2018* *9M 2017*
Revenue 642.0 679.2
EBITDA ^1) 270.2 299.0
Profit 83.1 125.0
Assets  3,821.1 3,887.5
Equity 2,325.2 2,455.1
Net debt ^2) 708.8 620.6
Investments 158.5 166.6

1)    EBITDA – earnings before interest, corporate income tax, share of profit or loss of associated companies, depreciation and amortisation and impairment of intangible and fixed assets 

2)     Net debt – borrowings at the end of the reporting period minus cash and cash equivalents at the end of the reporting period

 

Financial Ratios

    *9M 2018* *9M 2017*
Net debt / EBITDA ^1)   1.3 1.5
EBITDA margin ^2)   58% 43%
Return on equity (ROE) ^3)   11.7% 7.1%
Return on assets (ROA) ^4)   7.3% 4.3%
Return on capital employed (ROCE) ^5)   5.3% 6.5%
Net debt / equity ^6)   30% 25%

1)     Net debt / EBITDA – average value of net debt / EBITDA (12-month rolling)

2)     EBITDA margin – EBITDA (12-month rolling) / revenue (12-month rolling)

3)     Return on equity (ROE) – net profit (12-month rolling) / average value of equity

4)     Return on assets (ROA) – net profit (12-month rolling) / average value of assets

5)     Return on capital employed (ROCE) – operating profit (12-month rolling) / average value of equity + average value of borrowings

6)     Net debt at the end of the reporting period / equity at the end of the reporting period

 

Consolidated Statement of Profit or Loss*

EUR’000

  *01/01-30/09/2018* *01/01-30/09/2017*
     
Revenue 642,007 679,183
Other income 84,603 4,998
Raw materials and consumables used (336,580) (256,629)
Personnel expenses (81,047) (75,993)
Depreciation, amortisation and
impairment of intangible assets and
property, plant and equipment (181,406) (143,676)
Other operating expenses (38,823) (52,568)
*Operating profit* *88,754* *155,315*
Finance income 884 941
Finance costs (6,393) (8,646)
*Profit before tax* *83,245* *147,610*
Income tax (134) (22,574)
*Profit for the period* *83,111* *125,036*
*Profit attributable to:*    
– Equity holder of the Parent Company 81,737 124,125
– Non–controlling interests 1,374 911

 *   Consolidated Unaudited Condensed Financial Interim Statements have been prepared in accordance with the IFRS as adopted by the European Union.

 

Consolidated Statement of Financial Position*

EUR'000

  *30/09/2018* *31/12/2017*
     
*ASSETS*    
*Non–current assets*    
Intangible assets and property, plant and equipment 3,301,170 3,322,398
Investment property 477 753
Non–current financial investments 40 40
Investments in held–to–maturity
financial assets 16,947 16,984
Other non–current receivables 3,229 3,229
*Total non–current assets* *3,321,863* *3,343,404*
*Current assets*    
Inventories 107,733 76,328
Receivables from contracts with
customers 94,429 105,369
Other current receivables 179,677 646,761
Prepayment for income tax 11,741 –
Deferred expenses 3,235 3,241
Derivative financial instruments 10,142 4,619
Cash and cash equivalents 92,287 236,003
*Total current assets* *499,244* *1,072,321*
*TOTAL ASSETS* *3,821,107* *4,415,725*
     
*EQUITY AND LIABILITIES*    
*EQUITY*    
Share capital 834,791 1,288,715
Reserves 1,125,294 1,126,521
Retained earnings 357,825 423,613
*Equity attributable to equity
holder of the Parent Company* *2,317,910* *2,838,849*
Non–controlling interests 7,300 8,042
*Total equity* *2,325,210* *2,846,891*
*LIABILITIES*    
*Non–current liabilities*    
Borrowings 665,074 718,674
Provisions 23,437 21,910
Derivative financial instruments 3,079 4,914
Deferred income on contracts from
customers 142,537 142,132
Other liabilities and deferred income 349,740 350,926
*Total non–current liabilities* *1,183,867* *1,238,556*
*Current liabilities*    
Borrowings 136,069 108,083
Trade and other payables 128,026 147,072
Income tax payable – 27,725
Deferred income on contracts from
customers 13,028 12,500
Other deferred income 31,724 31,728
Derivative financial instruments 3,183 3,170
*Total current liabilities* *312,030* *330,278 *
*Total liabilities* *1,495,897* *1,568,834*
*TOTAL EQUITY AND LIABILITIES* *3,821,107* *4,415,725 *

*   Consolidated Unaudited Condensed Financial Interim Statements have been prepared in accordance with the IFRS as adopted by the European Union.

 

Additional information:
Jānis Irbe
Group Treasurer
Phone: +371 67 728 239
E-mail: investor.relations@latvenergo.lv

www.latvenergo.lv

*About Latvenergo*

Latvenergo Group is one of the leading energy suppliers in the Baltics operating in electricity and thermal energy generation and trade, natural gas trade, electricity distribution services and lease of transmission system assets. Latvenergo AS has been acknowledged as the most valuable company in Latvia for several times. International credit rating agency Moody’s has assigned Latvenergo AS an investment-grade credit rating of Baa2/stable.

Latvenergo Group is comprised of the parent company Latvenergo AS (generation and trade of electricity and thermal energy, trade of natural gas) and seven subsidiaries - Latvijas elektriskie tīkli AS (lease of transmission system assets), Sadales tīkls AS (electricity distribution), Elektrum Eesti OÜ (trade of electricity and natural gas in Estonia), Elektrum Lietuva UAB (trade of electricity and natural gas in Lithuania), Enerģijas publiskais tirgotājs AS (administration of mandatory electricity procurement process) and Liepājas enerģija SIA (generation and trade of thermal energy in Liepaja, electricity generation). All shares of Latvenergo AS are owned by the state and held by the Ministry of Economics of the Republic of Latvia. Reported by GlobeNewswire 12 minutes ago.

NEW YORK, Nov. 30, 2018 (GLOBE NEWSWIRE) -- New York-based Vilacto Bio Inc. (OTC QB:VIBI) has secured the patent applications for LACTOACTIVE® covering rights in the US, Canada Europe and Hong Kong. The transaction was finalized this November.Ownership of the patent applications, which Vilacto Bio had been licensing the US rights from a Danish company, is expected to give the company greater scope to continue developing the LACTOACTIVE® compound, and bolster its international IP ownership position.

The patent applications also cover the company’s new compound, LACTOACTIVE iTHER®, a LACTOACTIVE® variant that offers potent immune-system enhancement with a potential for treating a wide range of diseases. LACTOACTIVE iTHER® is expected to generate new revenue streams in addition to the company’s LACTOACTIVE®-based therapeutic skincare range.

“Vilacto Bio now is in a stronger position than ever to leverage the potential of LACTOACTIVE iTHER® for immunotherapy and vaccine-based treatments,” said Vilacto Bio CEO Gert Anderson.
“Our research shows that LACTOACTIVE iTHER® can contribute significantly to emerging therapies for treating diseases such as cancer, immunodeficiency disorders, osteoarthritis, psoriasis and thrombocytopenia.”

The main active component of LACTOACTIVE® and LACTOACTIVE iTHER® is colostrum, a natural substance that Vilacto Bio has refined and processed into a potent nanoparticle concentrate. In NPDDS form, the compound can be applied in deeper layers of the skin and, when injected, can penetrate cell walls to act directly on cytoplasm. The product is currently in the development stage and has not been approved for use by the FDA or any foreign agency.

Vilacto Bio plans to form strategic partnerships with other biotech firms and become the “go-to” partner for enhancing new immunotherapy and vaccine solutions with its refined-colostrum compound “weaponized” as a nanomedicine.

*About Vilacto Bio Inc.:
*Vilacto Bio Inc. (OTC QB:VIBI), is a biotech company that has developed the now fully patented Lactoactive^® (Lactoactive molecule) that in numerous studies has demonstrated above average effect treating conditions such as inflammatory diseases, diabetes, psoriasis, skin aging, and skin issues in different levels. We aim to further develop our Lactoactive^® molecule for the purpose of increasing the quality of our retail and medical skin cream products as well as licensing out our Lactoactive^® molecule for the pharmaceutical industry.

*Forward-Looking Statements & Disclaimers:*
The information in this Press Release includes certain "forward-looking" statements within the meaning of the Safe Harbor provisions of Federal Securities Laws, as that term is defined in section 27a of the United States Securities Act of 1933, as amended, and section 21e of the United States Securities Exchange Act of 1934, as amended. Statements in this document, which are not purely historical, are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Investors are cautioned that such statements are based upon assumptions that in the future may prove not to have been accurate and are subject to significant risks and uncertainties, including the future financial performance of the Company. Although the Company believes that the expectations reflected in its forward-looking statements are reasonable, it can give no assurance that such expectations or any of its forward-looking statements will prove to be correct. Readers are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date of this release, and the Company undertakes no obligation to update publicly any forward-looking statements to reflect new information, events, or circumstances after the date of this release except as required by law.

Vilacto Bio Inc.
The Seagram Building
375 Park Avenue, Suite 2607
New York City, NY 10152

Gert Andersen
Phone: +1 646-893-7895
info@vilactobio.com
www.vilactobio.com Reported by GlobeNewswire 12 minutes ago.

Brand management software company Yext Inc (NYSE:YXT) surpassed revenue expectations and upped its full-year guidance in its third-quarter results, but a lingering net loss sank its shares. The company reported a net loss of $0.12 per share, the same loss as the previous year’s third quarter and in-line with analysts' expectations. Revenue jumped 33% to $58.74 million compared with revenue of $44.33 million a year ago, surpassing consensus estimates of $58.35 million. Shares of Yext dipped about 9% to $16.60 in Friday pre-market trading. READ: Kopin Corp’s virtual reality tech isn’t just fun and games The company ended the quarter with $107 million in cash on hand. For the fourth quarter, Yext expects revenue of between $62 million to $63 million. The company upped the low-end of its full-year revenue guidance of $227 million to $228 million compared with its prior guidance of $226 million to $228 million. Net loss totaled $24.8 million, a 45% increase compared with the $17.1 million net loss in the previous third quarter. The company points to increased operating expenses, specifically the sales and marketing associated with acquiring new customers, as the reason behind the loss. “We believe leading brands are recognizing the highly attractive returns our revolutionary platform can deliver through higher revenue, improved process efficiencies, and better visibility in intelligent services,” said CEO Howard Lerman in the company’s press release. The company operates a cloud-based platform for business management, geared toward healthcare, retail and financial services industry in North America and Europe. Yext has snagged some high-profile customers, including Denny’s Corp (NASDAQ:DENN), Arby’s, T-Mobile US Inc (NASDAQ:TMUS) and Stanley Steemer.   Contact Lenore Fedow at lenore@proactiveinvestors.com Follow her on Twitter: @LenoreMariee Reported by Proactive Investors 34 minutes ago.

In this edition we take a look at the week in Europe as May takes her Brexit deal on the road in Britain, yellow jacket protests create headaches for Macron and Russia-Ukraine tensions present problems for the EU. Reported by euronews 16 minutes ago.

Via, a shuttle-based carpooling service and platform that partners with cities in the U.S. and Europe, could soon add scooters to its business. Via CEO and co-founder Daniel Ramot said on stage at TechCrunch Disrupt Berlin that the company is experimenting with the idea of adding scooters as a complement to its shuttle business. “We’re also adding scooters […] Reported by TechCrunch 30 minutes ago.

Reported by FT.com 1 day ago.

With sluggish growth translating into the most disappointing earnings in years, European stocks are set for a tough ride if a full blown Sino-U.S. trade war erupts following Presidents Donald Trump and Xi Jinping's G20 dinner on Saturday. Reported by Reuters 1 day ago.

Loads of Rangers fans have been giving their verdict on Thursday’s Europa League clash against Villarreal, and they are once again stunned by the form of Allan McGregor. Reported by Football FanCast 1 day ago.